The agreement does not promise that the suspended provision on test data rule concerning biological medicines will remain suspended.
If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.
As ministers of the member countries of the RCEP meet for final negotiations over the trade agreement this week, regional lawmakers today expressed concern about the lack of parliamentary and public oversight of the deal, as well as its potential human rights impacts.
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
Civil society groups want the contents of the MoU to be made public before its finalisation to ensure that India resists US demands to influence the implementation of India’s IP legislations.
India and the US have signed an agreement on intellectual property rights (IPR) ahead of US President Donald Trump’s visit. The Cabinet Wednesday approved an MoU with the US on the issue of IPRs.
A US-India trade deal will have historic significance, especially if it ushers in a period of strong collaboration to advance a shared bilateral trade agenda and effectively resolves troubles as they arise.
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."
This study assesses the impact of the EFTA-Mercosur free trade agreement on access to medicines, indigenous rights and women rights.
The industry is working to get US senators on record in support of including the protections it lost in NAFTA 2.0 in future trade agreements with other countries.
India’s decision to pull out of RCEP means its policy on access to inexpensive drugs will not be under pressure.
Proper mandatory licenses will be exempt from claims for expropriation under the China BIT model.
Many requirements of the original USMCA have already been met by recent changes in Canadian IP legislation, but more amendments will be required to implement the USMCA.
The hard part of the trade dispute will cover long-standing issues relating to intellectual property violations and forced technology transfer by China, as well as subsidization of Chinese industries.
Canada’s intellectual protection rights system was also slammed for being too clement.
India is making efforts to speed up free trade negotiations with the EFTA countries comprising Switzerland, Norway, Iceland and Leichtenstein in parallel with its discussions with the European Union on a similar pact.
The phase two agreement is to be digitally focused and could include a US-China bilateral trade agreement.
Generic versions of biologic drugs could come to market faster.
Confidential documents from trade negotiations between the UK government and the US detail the US position regarding IP provisions.
China said it will raise penalties on violations of intellectual property rights in an attempt to address one of the sticking points in trade talks with the US.